Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sucrose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.70 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 6/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sucrose SCHEMBL1001768 | 1.00 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL6241474 | 0.97 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL5972240 | 0.97 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL5012470 | 0.97 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL3797239 | 0.97 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL7861331 | 0.97 | CDK1 (0.70) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL3506279 | 0.96 | CDK1 (0.68) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL9800251 | 0.96 | CDK1 (0.68) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL6638490 | 0.96 | CDK1 (0.68) | CDK1CCNB1CA2CA9LDHA | |
| Sucrose SCHEMBL8795457 | 0.94 | CDK1 (0.68) | CDK1CCNB1CA2CA9LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102985091-A | Compositions and methods for treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds | NEOCUTIS SA | 2013-03-20 | — | — | CN | claimed |
| EP-2542246-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN DISEASES AND DISORDERS USING ANTIMICROBIAL PEPTIDE SEQUESTERING COMPOUNDS | Neocutis SA (CH) | 2013-01-09 | — | — | EP | claimed |
| WO-2011109469-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN DISEASES AND DISORDERS USING ANTIMICROBIAL PEPTIDE SEQUESTERING COMPOUNDS | NEOCUTIS SA (CH) | 2011-09-09 | — | — | WO | claimed |
| US-20110217249-A1 | Compositions and Methods for the Treatment of Skin Diseases and Disorders Using Antimicrobial Peptide Sequestering Compounds | ANTEIS SA (CH) | 2011-09-08 | — | — | US | claimed |
| CN-1021629-C | Stable basic sucralfate aluminum sulfate suspension pharmaceutical composition without suspending agent | LISAPHARMA SPA (IT) | 1993-07-21 | — | — | CN | claimed |
| EP-0493380-A4 | METHOD AND COMPOSITIONS FOR NONINVASIVE DOSE-TO-EFFECT ADMINISTRATION OF LIPOPHILIC DRUGS | — | 1992-10-07 | — | — | EP | claimed |
| EP-0493380-A1 | METHOD AND COMPOSITIONS FOR NONINVASIVE DOSE-TO-EFFECT ADMINISTRATION OF LIPOPHILIC DRUGS. | UNIV UTAH RESEARCH INST (US) | 1992-07-08 | — | — | EP | claimed |
| WO-1991003233-A1 | METHOD AND COMPOSITIONS FOR NONINVASIVE DOSE-TO-EFFECT ADMINISTRATION OF LIPOPHILIC DRUGS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1991-03-21 | — | — | WO | claimed |
| EP-0286781-A2 | Pharmaceutical preparation for treating gastro-intestinal tract diseases | HEUMANN PHARMA GMBH & CO (DE) | 1988-10-19 | — | — | EP | claimed |
| US-20260091023-A1 | GEL-CHEWABLE DOSAGE FORM | KENVUE BRANDS LLC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681772-A2 | GEL-CHEWABLE DOSAGE FORM | Kenvue Brands LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12521376-B2 | Gel-chewable dosage form | KENVUE BRANDS LLC (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4037681-B1 | GEL-CHEWABLE DOSAGE FORM | KENVUE BRANDS LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4593797-A1 | GUMMY DOSAGE FORMS | Kenvue Brands LLC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-4863737-A | TRANSMUCOSAL DELIVERY | UNIVERSITY OF UTAH (US) | 1989-09-05 | — | — | US | disclosed |
| US-4447437-A | Pharmaceutical composition and method for treatment of peptic ulcer | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-08 | — | — | US | disclosed |
| US-4342774-A | N-Acylcarnosine aluminum salt, its preparation, and a digestive ulcer remedy containing such salt | NIPPON CHEMIPHAR CO., LTD. (JP) | 1982-08-03 | — | — | US | disclosed |
| US-4339378-A | ANTIULCER AGENTS | NIPPON CHEMIPHAR CO., LTD. (JP) | 1982-07-13 | — | — | US | disclosed |
| US-4339379-A | ANTIULCER AGENTS | NIPPON CHEMIPHAR CO., LTD. (JP) | 1982-07-13 | — | — | US | disclosed |
| US-3995055-A | AMINO ACID ESTER DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JA) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091023-A1 | GEL-CHEWABLE DOSAGE FORM | HRH2, SI, LIPA | CDK1 3664/4885CCNB1 3900/4885CA2 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.